Zimmer Biomet Holdings (ZBH) Tops Q4 EPS by 3c; Guides In-Line

Zimmer Biomet Holdings (NYSE: ZBH) reported Q4 EPS of $2.14, $0.03 better than the analyst estimate of $2.11. Revenue for the quarter came in at $2.01 billion versus the consensus estimate of $1.98 billion.

GUIDANCE:

Zimmer Biomet Holdings sees FY2017 EPS of $8.50-$8.68, versus the consensus of $8.65. 2017 revenue is expected to increase between 2.2% and 3.2% when compared to full-year 2016 revenue, or to be in a range of $7.855 billion to $7.930 billion, versus the consensus of $7.91 billion.

For earnings history and earnings-related data on Zimmer Biomet Holdings (ZBH) click here.

You May Also Be Interested In

• IDT Corp. (IDT) Tops Q3 EPS by 2c; offer guidance
• C3.ai (AI) Tops Q4 EPS by 5c, Beats on Revenue; Offers FY27 Revenue Guidance
• Zimmer Biomet to Present at the Goldman Sachs 47th Annual Global Healthcare Conference